Artielle Immunotherapeutics is a venture-backed company pioneering a first-in-class therapeutic platform (DRhQ) to treat neuroinflammatory conditions and advanced cancers — based on groundbreaking research from OHSU and VA Portland Healthcare System.
Targeting Progressive MS — the area of greatest unmet medical need.
No FDA-approved pharmacotherapy exists. DRhQ offers a neuroimmune-targeted approach.
Reducing infarct volume and neurological deficits in cerebral ischemia models.
Redirecting the immune system against treatment-resistant cancer.
Artielle's lead molecule, DRhQ, targets the CD74 receptor on monocytes and inflammatory T cells and blocks the action of macrophage migration inhibitory factor (MIF) — a key inflammatory cytokine elevated in MS and many other diseases. This dual-action approach reverses the chemotactic gradient attracting inflammatory cells to CNS injury sites and promotes apoptosis of destructive infiltrating cells.
Learn MoreDRhQ competitively inhibits MIF binding to the CD74 receptor on monocytes and T cells.
Blocks pro-inflammatory signaling, reversing the attraction of peripheral cells to CNS injury sites.
Promotes apoptosis of infiltrating cells and reprograms microglia and astrocytes toward neuroprotection.